Regulus Therapeutics’ (RGLS) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research report released on Wednesday,Benzinga reports. HC Wainwright currently has a $10.00 price objective on the biopharmaceutical company’s stock.

Regulus Therapeutics Price Performance

Regulus Therapeutics stock opened at $1.35 on Wednesday. The company’s 50 day simple moving average is $1.32 and its 200 day simple moving average is $1.48. Regulus Therapeutics has a fifty-two week low of $0.83 and a fifty-two week high of $3.79. The firm has a market capitalization of $88.43 million, a price-to-earnings ratio of -1.26 and a beta of 1.58.

Insider Buying and Selling

In other Regulus Therapeutics news, CEO Joseph P. Hagan sold 115,290 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $145,265.40. Following the sale, the chief executive officer now directly owns 222,572 shares in the company, valued at approximately $280,440.72. This trade represents a 34.12 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Christopher Ray Aker sold 38,547 shares of the firm’s stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $1.26, for a total transaction of $48,569.22. Following the sale, the vice president now owns 54,634 shares in the company, valued at $68,838.84. This trade represents a 41.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 223,998 shares of company stock valued at $282,237 in the last 90 days. 4.35% of the stock is owned by insiders.

Institutional Trading of Regulus Therapeutics

Several hedge funds have recently bought and sold shares of RGLS. Creative Planning acquired a new stake in Regulus Therapeutics during the 3rd quarter worth approximately $26,000. SG Americas Securities LLC acquired a new stake in shares of Regulus Therapeutics in the third quarter valued at approximately $33,000. Jane Street Group LLC acquired a new stake in shares of Regulus Therapeutics in the third quarter valued at approximately $46,000. PEAK6 LLC acquired a new stake in shares of Regulus Therapeutics in the fourth quarter valued at approximately $95,000. Finally, Velan Capital Investment Management LP acquired a new stake in shares of Regulus Therapeutics in the fourth quarter valued at approximately $111,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.